cyclic-gmp and Amnesia

cyclic-gmp has been researched along with Amnesia* in 1 studies

Other Studies

1 other study(ies) available for cyclic-gmp and Amnesia

ArticleYear
The phosphodiesterase 5 inhibitor, KJH-1002, reverses a mouse model of amnesia by activating a cGMP/cAMP response element binding protein pathway and decreasing oxidative damage.
    British journal of pharmacology, 2018, Volume: 175, Issue:16

    Inhibition of PDE5 improves synaptic plasticity and memory via enhancing cGMP expression, thus activating the cGMP/cAMP response element binding protein (CREB) signalling pathway. This study investigated the effects of a PDE5 inhibitor on scopolamine-induced cognitive dysfunction, using memory-related behavioural tests and biochemical assays.. In mice were pretreated with PDE5 inhibitor, amnesia was induced by scopolamine. The learning and memory abilities of mice were tested using the Morris water maze test, the Y-maze test, the passive avoidance test and the novel object recognition test in sequence. Expression of memory-related bio-molecules and oxidative stress parameters in brain tissue were measured using Western blot and spectrophotometry respectively.. KJH-1002 restored cognitive function in scopolamine-induced amnesia mice by activating the cGMP/CREB signalling pathway and attenuating oxidative stress. The beneficial effects of KJH-1002 on cognition indicate its potential as a therapeutic candidate for Alzheimer's disease.

    Topics: Amnesia; Animals; Cyclic AMP Response Element-Binding Protein; Cyclic GMP; Disease Models, Animal; Male; Maze Learning; Memory; Mice, Inbred ICR; Oxidative Stress; Phosphodiesterase 5 Inhibitors; Scopolamine; Signal Transduction

2018